Ann: Appendix 4D and Half Yearly Report, page-6

If you want to compare how much more has been completed compared with the FY19 report read this:

Clinical progress
The Company is greatly encouraged by these advances, which have been pivotal in the delivery of
further intravenous infusion study safety data in small animals, indicating a wide therapeutic dose
window.
Positive kidney and urinary tract infection efficacy data indicates the potential use of RECCE® 327 across
the full therapeutic approach to the treatment of patients with sepsis.
With a compelling data package, the business is on track to formalise a clinical trial agreement to start a
first-in-human Phase I trial and, submit an application to start a topical Phase I/II trial. We look forward
to providing updates as these programs advance.

source: Half Yearly Report and Accounts 2019


Progress!